Abstract
The production of high-quality recombinant proteins is critical
to maintaining a continuous supply of biopharmaceuticals, such as
therapeutic antibodies. Engineering mammalian cell factories presents a
number of limitations typically associated with proteotoxic stress
induced upon aberrant accumulation of off-pathway protein folding
intermediates, which eventually culminate with the induction of
apoptosis. Recent progress in mammalian synthetic biology provides
unique opportunities to endow cells with programmable, user-defined
behaviors, thereby addressing some of the challenges of current methods.
In this review, we will discuss advances in synthetic biology to design
efficient strategies for biomanufacturing.
